Latest Production Development News

IMEXHS Limited reported modest revenue growth and a 16% increase in ARR in Q1 FY25, alongside the commercial rollout of its Aquila+ radiology platform and a $2.5 million capital raising to fuel expansion.

Norwood Systems has landed a significant five-year contract with Optus to overhaul its voicemail platform, delivering early milestones on schedule and strengthening its financial position. The company is also advancing its global pipeline with Tier-1 telecom operators and deepening strategic partnerships with Microsoft Azure and AWS.

Cape Range Ltd’s Malaysian software arm Biztrak delivered robust 29% revenue growth in Q1 2025, driven by e-invoicing initiatives, even as a planned rights issue was cancelled due to shareholder withdrawal amid market volatility.

betr Entertainment has successfully raised $130 million through a fully underwritten equity offer priced at a 13.7% premium, underpinning its strategic acquisition of PointsBet and positioning for growth in the Australian wagering market.

Volt Group Limited reported a robust 26.8% revenue increase in Q1 FY25, driven by strong performances in its EcoQuip and Wescone divisions, alongside promising advances in its ATEN Waste Heat to Power technology.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Pointerra Limited’s Q3 FY25 results reveal delayed invoicing milestones pushed into Q4, yet strong progress across multiple sectors and promising product development underpin an optimistic cashflow outlook.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Appen Limited reported a 12% revenue increase excluding Google in Q1 FY25, alongside a significant improvement in underlying EBITDA and a robust cash position, setting a positive tone for the year ahead.